Brain disorders (Amsterdam, Netherlands)最新文献

{"title":"A review of the effects of spinal cord stimulation on motor symptoms in individuals with Parkinson's disease","authors":"Claudia Eunice Neves de Oliveira ,&nbsp;Layla Cupertino ,&nbsp;Emanuele Los Angeles ,&nbsp;Nathalia Mendes Pellegrino ,&nbsp;Thayna Magalhães Novaes ,&nbsp;Viviane Dos Santos Mendes ,&nbsp;Luana dos Santos de Oliveira ,&nbsp;Daniel Boari Coelho","doi":"10.1016/j.dscb.2025.100278","DOIUrl":"10.1016/j.dscb.2025.100278","url":null,"abstract":"<div><h3>Background</h3><div>Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by motor symptoms such as postural instability. While conventional treatments like levodopa and deep brain stimulation (DBS) can be effective in early stages, they often fail to address axial symptoms in advanced PD. Spinal cord stimulation (SCS) has emerged as a potential alternative, targeting the spinal cord to modulate neural activity and improve motor function. This systematic review aims to evaluate the effectiveness of SCS on motor symptoms in PD.</div></div><div><h3>Methods</h3><div>This systematic review followed a registered protocol (PROSPERO CRD42021261069) and included studies involving SCS intervention in PD patients. The search was conducted across four electronic databases until December 2023, focusing on terms related to SCS and motor symptoms in PD. Eligible studies included those with SCS applied at any spinal level, irrespective of the intervention duration, and involving outcome variables related to motor symptoms.</div></div><div><h3>Results</h3><div>The review analyzed 21 studies with approximately 70 patients. Stimulation parameters varied widely, including different spinal levels, frequencies, pulse widths, and amplitudes. Most studies reported improvements in motor symptoms, particularly in gait and postural stability.</div></div><div><h3>Conclusion</h3><div>The findings suggest that SCS may offer a promising alternative for managing motor symptoms in PD, especially for those resistant to levodopa and DBS. Despite encouraging results, the variability in outcomes highlights the need for further research to optimize SCS protocols, identify suitable patient profiles, and understand the long-term effects. Larger, well-designed clinical trials are necessary to establish standardized guidelines for using SCS in PD treatment.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"19 ","pages":"Article 100278"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145026486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of exercise and pharmacotherapy on fatigue in stroke patients: A systematic review with meta-analysis","authors":"Venkadesan Rajendran,&nbsp;Deepa Jeevanantham","doi":"10.1016/j.dscb.2025.100274","DOIUrl":"10.1016/j.dscb.2025.100274","url":null,"abstract":"<div><h3>Objective</h3><div>This systematic review and meta-analysis aimed to investigate the efficacy of exercise and pharmacological interventions in mitigating fatigue in acute, subacute, and chronic phases of stroke recovery.</div></div><div><h3>Methods</h3><div>PubMed, Embase, Science Direct, Web of Science, Scopus, and Google Scholar databases were searched for articles published before December 2023. Randomized controlled trials that assessed the effectiveness of exercise and pharmacotherapy on PSF in patients with acute, subacute, and chronic strokes were included. Studies that met the following criteria were included: participants who had experienced PSF, were older than 18 years, and used exercise or pharmacotherapy as interventions. The I2 test and funnel plot were used to examine heterogeneity and publication bias. The quality of the studies was assessed using the Critical Appraisal Checklist for Studies created by the Joanna Briggs Institute.</div></div><div><h3>Results</h3><div>Twelve publications were selected from 1,472 citations for the final qualitative analysis. The articles were published between 2007 and 2023, with 686 participants, ranging from 06 to 119. Physical exercise and pharmacological treatments (fluoxetine, modafinil, and (−)-OSU6162) were associated with decreased fatigue severity at the end of treatment (pooled mean difference = −2.90, 95 % CI: −6.83 to 1.02). However, these trials were small and had a significant risk of bias.</div></div><div><h3>Conclusion</h3><div>Our findings suggest that exercise and pharmacotherapy may reduce PSF. However, the small sample size and potential bias of the trials underscores the need for larger sample sizes and appropriate treatment durations.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"19 ","pages":"Article 100274"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144925488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monosodium glutamate aggravates social defeat stress-induced behavioral dysfunctions by promoting neurodegeneration and downregulating prefrontal cortex BDNF expressions in mice","authors":"Lily O. Otomewo ,&nbsp;Paul Ademola Adeleke ,&nbsp;Abayomi M. Ajayi ,&nbsp;Joseph Chimezie ,&nbsp;James O. Oni ,&nbsp;Anthony T. Eduviere ,&nbsp;Olusegun A. Adeoluwa ,&nbsp;Solomon Umukoro","doi":"10.1016/j.dscb.2025.100275","DOIUrl":"10.1016/j.dscb.2025.100275","url":null,"abstract":"<div><div>Monosodium glutamate (MSG), a food additive, acts as an excitotoxin by elevating brain glutamate levels, resulting in neuronal and behavioral dysfunctions. Social defeat stress (SDS) induces behavioral and neuronal changes by depleting brain-derived neurotrophic factor (BDNF), suggesting that MSG might exacerbate mental health risks associated with SDS. Thus, this study was designed to evaluate the effects of MSG on chronic SDS-induced behavioral disturbances, BDNF signaling, and histomorphological changes in mice. Male Swiss mice were randomly distributed into five groups (<em>n</em> = 5). Group 1 (Control) and group 2 (Stress-control) received distilled water (10 mL/kg, p.o) while group 3–5 had MSG (100, 200 and 400 mg/kg, p.o). Mice in group 2–5 underwent SDS through exposure to aggressive resident counterparts for 5 min confrontation, daily for 14 days. The signs of depression, anxiety, and social interaction impairments were evaluated. The blood glucose, serum corticosterone and BDNF immunopositivity of the hippocampus and prefrontal cortex (PFC) were measured. The histomorphological changes of the hippocampus and PFC were determined. MSG significantly (<em>p</em> &lt; 0.05) exacerbated SDS-induced depression and anxiety-like behaviors in mice. It also significantly (<em>p</em> &lt; 0.05) worsened the social interaction deficits and elevated blood glucose, and corticosterone levels in mice exposed to SDS. Socially defeated mice pretreated with MSG showed decreased BDNF expression in the PFC. High doses of MSG significantly (<em>p</em> &lt; 0.05) increased the proportions of degenerated neuronal cells in the hippocampal CA3 and PFC of SDS-mice. These findings suggest that MSG aggravates SDS-induced depression-related disorders in mice by disrupting neuronal integrity and downregulating PFC BDNF expressions.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"19 ","pages":"Article 100275"},"PeriodicalIF":0.0,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, etiology, risk factors, management options, and outcomes in chronic subdural hematoma (cSDH): A comprehensive literature review of recent advances","authors":"Mahdi Mehmandoost ,&nbsp;Amirmohammad Bahri ,&nbsp;Afarinesh Hasheminejad ,&nbsp;Hossein Sharifi ,&nbsp;Sayeh Oveisi ,&nbsp;Farzan Fahim","doi":"10.1016/j.dscb.2025.100271","DOIUrl":"10.1016/j.dscb.2025.100271","url":null,"abstract":"<div><h3>Background</h3><div>Chronic subdural hematoma (cSDH) is a significant neurosurgical disorder with a rising incidence (1.7–20.6 per 100,000 people annually) and a recurrence rate of 10–20 %. The aging global population has led to an increased disease burden, with notable impacts on morbidity and mortality among elderly patients.</div></div><div><h3>Objective</h3><div>This narrative review aims to provide a comprehensive synthesis of recent advances in the prevalence, etiology, risk factors, management strategies, and outcomes of cSDH, highlighting their clinical implications.</div></div><div><h3>Methods</h3><div>A narrative review methodology was employed. Literature was searched systematically in PubMed, Scopus, and Web of Science covering January 2000 to April 2025, using keywords related to “chronic subdural hematoma,” “risk factors,” “management,” and “outcomes.” Inclusion criteria encompassed relevant cohort studies, meta-analyses, and clinical guidelines, with a focus on studies published in English. Risk factors, etiologies, therapeutic approaches, and prognostic variables were extracted and synthesized.</div></div><div><h3>Results</h3><div>cSDH predominantly affects elderly men, with major risk factors including advanced age, male sex, head trauma, use of antiplatelet or anticoagulant agents, and chronic alcohol use. Etiological mechanisms involve bridging vein injury, chronic inflammation, angiogenesis, and impaired hemostasis. Management options consist of conservative therapy, pharmacological agents (such as dexamethasone and atorvastatin), minimally invasive procedures (e.g., middle meningeal artery embolization), and surgical interventions. Decision-making should be individualized based on patient comorbidities and risks. Prognosis is influenced by age, comorbid conditions, hematoma characteristics, and selected therapy. Surgical drainage remains the mainstay of treatment but carries recurrence risk, especially in older adults with multiple comorbidities.</div></div><div><h3>Conclusion</h3><div>Understanding current evidence regarding cSDH pathophysiology, risk stratification, and treatment modalities is essential for optimizing outcomes. Continued research is warranted to refine preventive, diagnostic, and management approaches, particularly for high-risk populations.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"19 ","pages":"Article 100271"},"PeriodicalIF":0.0,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144890457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current drug targets for the treatment of depression","authors":"Gauri Pathak ,&nbsp;Aryaa Nigade ,&nbsp;Kuttiappan Anitha ,&nbsp;Shvetank Bhatt","doi":"10.1016/j.dscb.2025.100270","DOIUrl":"10.1016/j.dscb.2025.100270","url":null,"abstract":"<div><div>Depression or major depressive disorder (MDD) is a condition of prolonged sadness, which requires crucial examination. Worldwide, 5 % of the adult population is suffered with depression. According to the World Health Organization (WHO) data, women are more prone to affect with depression as compared to men. There is no effective treatment available for the MDD. Available treatment options such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs) are facing problems of treatment resistance and onset of action of above-mentioned drugs are slow and start showing their effects after 4–6 weeks. Now, the discovery of antidepressants is going on beyond monoaminergic transmission and recently approved drugs targets glutaminergic and GABAergic transmission. Moreover, serotonergic and dopaminergic transmission at multiple receptor levels and uptake mechanisms, melatonin agonists, neuropeptides, neurokinins etc. are also approved or in the various phases of clinical trials for MDD. This paper mainly discusses the recent advances in the treatment of depression i.e. drugs and novel targets which are recently approved or evaluated in preclinical and clinical setups. It also highlights the need for innovative treatments due to limitations in the current therapies and emphasises on novel drug targets beyond the traditional treatment plans, which might lead to increase in effectiveness and faster relief from symptoms.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"19 ","pages":"Article 100270"},"PeriodicalIF":0.0,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144828152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coenzyme-Q10 diminishes early behavior indicative of depressive-like phenotype induced by overweight in a murine model of litter size reduction","authors":"Carolina Soares Horta de Souza ,&nbsp;Fernando Vitor Vieira ,&nbsp;Thaís da Silva Maciel ,&nbsp;Viviana Carolina Trujillo Rojas ,&nbsp;Cíntia Onofra Novais ,&nbsp;Sebastião Nilce Souto Filho ,&nbsp;Alexandre Giusti-Paiva ,&nbsp;Tayllon dos Anjos-Garcia ,&nbsp;Bruna Kalil-Cutti ,&nbsp;Fabiana Cardoso Vilela","doi":"10.1016/j.dscb.2025.100268","DOIUrl":"10.1016/j.dscb.2025.100268","url":null,"abstract":"<div><div>The present study was developed to investigate whether the chronic treatment with Coenzyme Q10 (Co-Q10) could reverse behaviors indicative of depressive-like phenotype induced by early-life obesity in a murine model of litter size reduction. We used a standardized litter size reduction protocol, allocating litters into normal litter (NL), consisting of six males and six female pups, or into small litter (SL), consisting of two males and two female pups per litter. Maternal behavior was monitored during the initial week of lactation. Subsequently, we assessed the pups for weight gain, social play behavior, immobility time in the forced swimming test, and locomotor activity in the open field apparatus. Our results indicated that litter size reduction led to increased maternal behavior and greater weight gain in offspring from the SL group. Both male and female rodents in the SL group exhibited decreased social play behavior and spent more time immobile during the forced swimming test, suggesting a depressive-like phenotype. Notably, we observed that chronic treatment with Co-Q10 prevented the onset of the behavior indicative of a depressive-like phenotype. Obesity may promote the development of early depressive-like behavior, which could potentially be reversed by Co-Q10.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"19 ","pages":"Article 100268"},"PeriodicalIF":0.0,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent progress and challenges of acute encephalitis syndrome: an update on pathogenesis and interventional approaches","authors":"Priya Sharma ,&nbsp;Krupanshu Parmar ,&nbsp;Aishika Datta ,&nbsp;Bijoyani Ghosh ,&nbsp;Deepaneeta Sarmah ,&nbsp;Anupom Borah ,&nbsp;Pallab Bhattacharya","doi":"10.1016/j.dscb.2025.100267","DOIUrl":"10.1016/j.dscb.2025.100267","url":null,"abstract":"<div><div>Acute Encephalitis Syndrome (AES) refers to inflammation of the brain and is characterized by an acute onset of fever with altered consciousness. It can occur irrespective of age and gender which may eventually trigger seizures. Earlier, AES was categorized as infectious and non-infectious encephalitis keeping a major focus on Japanese encephalitis (JE). However, successful immunization against JE has reduced mortality. Nevertheless, AES is still predominant and has its role in neurological diseases burden. Recent etiological studies have explored that various viral and non-viral entities contributing to the current burden of AES by their unique mechanisms which are yet to be properly understood. Moreover, the incidence of AES can differ according to seasonal and geographical variances. Hence, in the present review, we will discuss the pathophysiology, incidence, and prevalence of AES in light of different causative agents. In addition, various risk factors and comorbidities associated with AES will also be discussed. Understanding the major causes of AES may help in the discovery of future therapeutic strategies to manage its high burden.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"19 ","pages":"Article 100267"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring functional neurological disorder: Cultural influences and risk factors in Iranian society – A cross-sectional study","authors":"Tina Moghadam Fard ,&nbsp;Abdol-Hossein Vahabie ,&nbsp;MohammadAli Shokri ,&nbsp;Mohammad Rohani ,&nbsp;Maziar Emamikhah ,&nbsp;Soode Tajik Esmaeeli ,&nbsp;Seyed Amir Hassan Habibi ,&nbsp;Fatemeh Sadat Mirfazeli","doi":"10.1016/j.dscb.2025.100265","DOIUrl":"10.1016/j.dscb.2025.100265","url":null,"abstract":"<div><div>Introduction: Functional Neurological Disorder (FND) is a neuropsychiatric condition marked by disrupted brain function. It is prevalent, affecting over 10 % of neurology outpatients, and often misdiagnosed due to symptom overlap with other neurological disorders. Cultural factors significantly influence symptom expression. This study explores FND's risk factors and presentations in Iranian culture, contributing to a broader understanding of this complex disorder. Methods: This observational cross-sectional study examined 53 FND patients diagnosed using DSM-5 criteria at Rasoul Akram Hospital, Tehran, from 2021 to 2024. Data on demographic information, medical comorbidities, psychological stressors, and clinical presentations of FND were retrospectively collected. Logistic regression explored relationships between FND presentations and other factors. Results: Almost 85 % of the participants reported experiencing at least one stressor prior to the onset of FND symptoms, with grief and familial stressor most common. Psychiatric comorbidities were reported by 75.5 %, predominantly major depressive disorder (62.3 %). Among FND presentations, sensory manifestations correlated with neurological comorbidities, while seizure presentations were linked to personality disorders and familial stressor, highlighting environmental influences on FND symptoms. Discussion: In Iranian culture, rich in trauma and unique characteristics, FND patients commonly experience major depressive disorder (MDD) as a comorbidity. Familial stressor and grief are prevalent, with familial stressor being critical due to cultural significance.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"19 ","pages":"Article 100265"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rechallenge following seizure in a patient receiving continuous theta burst stimulation for alcohol dependence","authors":"Venkata Lakshmi Narasimha ,&nbsp;Varsha Udupa ,&nbsp;Huded Swarna Rekha ,&nbsp;Siddharth V ,&nbsp;Jayant Mahadevan ,&nbsp;Lekhansh Shukla ,&nbsp;Urvakhsh Meherwan Mehta ,&nbsp;Prabhat Kumar Chand","doi":"10.1016/j.dscb.2025.100266","DOIUrl":"10.1016/j.dscb.2025.100266","url":null,"abstract":"<div><div>Transcranial Magnetic Stimulation (TMS) is a promising treatment for alcohol dependence, but rare side effects, such as seizures, necessitate careful monitoring. We report the case of a 40-year-old man with alcohol dependence who received sequential bilateral TMS - intermittent theta burst stimulation (iTBS) over the left dorsolateral prefrontal cortex (DLPFC), followed by continuous theta burst stimulation (cTBS) over the right DLPFC alongside Baclofen 120 mg. He experienced a seizure during cTBS targeting the right DLPFC at 100 % of the resting motor threshold (RMT). The seizure occurred during the 22nd session, following recent disulfiram initiation and sleep deprivation. Magnetic resonance imaging and electroencephalogram results were normal. TMS was discontinued, but the patient relapsed on alcohol within five days due to cravings. A carefully considered rechallenge with intermittent theta burst stimulation (iTBS) at 90 % RMT to the left DLPFC was initiated, excluding disulfiram and ensuring adequate sleep before sessions. The patient successfully completed 14 iTBS sessions without recurrence of seizures and achieved six months of abstinence. This case underscores the importance of regular RMT monitoring, cautious dosing, and addressing modifiable risk factors, such as sleep deprivation and medication interactions, to enhance the safety of TMS in clinical practice. A rechallenge with an adjusted TMS protocol can be a viable option after a seizure, offering significant benefits for relapse prevention in alcohol dependence.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"19 ","pages":"Article 100266"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polyostotic fibrous dysplasia in an adult with middle ear cholesteatoma and ipsilateral visual impairment","authors":"Yu-Xing Ge,&nbsp;Jie Wang,&nbsp;Yue Liao,&nbsp;Jing Yu","doi":"10.1016/j.dscb.2025.100263","DOIUrl":"10.1016/j.dscb.2025.100263","url":null,"abstract":"<div><div>Fibrous dysplasia (FD) is a rare benign fibro-osseous disorder that typically onsets in childhood or adolescence. After puberty, the progression of the skeletal lesions tends to be suspended. Unlike other reported FD patients, we describe an adult female with middle ear cholesteatoma, who gradually experienced a vision decline in right eye at the age of 46, accompanied by facial asymmetry and deformity mainly located around the zygomatic arch, and oculomotor paralysis in right. Besides the involvement of craniofacial bones, another asymptomatic lesion had been detected incidentally in left femur by whole-body bone scintigraphy. The patient has no osteodynia, fracture, cutaneous or endocrine findings which are the common manifestations of FD. A surgical procedure had been subsequently performed to relieve neurologic compression. The specimens from skull base further confirmed the diagnosis of FD histopathologically.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"19 ","pages":"Article 100263"},"PeriodicalIF":0.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144679616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}